Shenzhen MingSight Relin Pharmaceuticals

Shenzhen MingSight Relin Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for chronic blinding eye diseases. The company's primary focus is on retinal vascular diseases, such as diabetic macular edema (DME) and diabetic retinopathy (DR). Its lead candidate, MS-553, is an orally administered small molecule inhibitor of Protein Kinase C beta (PKCβ), designed to provide a non-invasive alternative to standard-of-care intravitreal injections. MingSight Relin operates with a global development strategy, maintaining research and clinical operations in both China and the United States to address significant unmet medical needs in the ophthalmology market.